MedPage Today on MSN
Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug
Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR tr ...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch ...
Various forms of inflammation, including traumatic brain injury (TBI), can impact neuroimmune communication between the brain and the periphery, and are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results